Xeris Biopharma Holdings, Inc.XERSNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+8.0%
5Y CAGR+17.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+8.0%/yr
vs +28.7%/yr prior
5Y CAGR
+17.7%/yr
Recent deceleration
Acceleration
-20.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.3x
Strong expansion
Streak
5 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $213.54M | +6.8% |
| 2024 | $199.88M | +11.5% |
| 2023 | $179.28M | +5.7% |
| 2022 | $169.55M | +12.0% |
| 2021 | $151.43M | +60.0% |
| 2020 | $94.65M | -23.4% |
| 2019 | $123.50M | +99.9% |
| 2018 | $61.77M | +119.2% |
| 2017 | $28.18M | +97.1% |
| 2016 | $14.30M | - |